Welcome to our dedicated page for BLDEW SEC filings (Ticker: BLDEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BLDEW's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BLDEW's regulatory disclosures and financial reporting.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported equity compensation activity involving the company’s Class A common stock. On April 23, 2026, he acquired 545,625 shares at $0.0000 per share upon vesting of performance-based restricted stock units granted on March 20, 2025, after the compensation committee certified that performance criteria were met.
On April 24, 2026, 301,731 shares were disposed of at $4.92 per share through shares withheld by the issuer to cover tax withholding obligations related to the PSU vesting, rather than an open-market sale. Following these transactions, Heyburn directly held 1,580,668 shares of Class A common stock.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported equity compensation activity involving the company’s Class A common stock. On April 23, 2026, he acquired 545,625 shares at $0.0000 per share upon vesting of performance-based restricted stock units granted on March 20, 2025, after the compensation committee certified that performance criteria were met.
On April 24, 2026, 301,731 shares were disposed of at $4.92 per share through shares withheld by the issuer to cover tax withholding obligations related to the PSU vesting, rather than an open-market sale. Following these transactions, Heyburn directly held 1,580,668 shares of Class A common stock.
Strata Critical Medical, Inc. calls a virtual 2026 annual stockholder meeting on May 28, 2026 at 9:00 a.m. Eastern to elect two Class II directors, ratify Deloitte & Touche LLP as auditor, and hold an advisory Say‑on‑Pay vote on 2025 executive compensation.
The company, formerly Blade Air Mobility, transformed in 2025 into a pure‑play medical logistics and services provider by selling its passenger business to Joby Aviation for approximately $76 million in Joby stock plus up to $45 million in holdbacks and earn‑outs, and acquiring Keystone Perfusion Services. It now operates Logistics and Clinical segments serving transplant and cardiovascular surgery customers.
Governance highlights include a classified Board, Co‑Chief Executive Officers William A. Heyburn and Melissa M. Tomkiel, and former CEO Robert Wiesenthal as Non‑Executive Chairman, with independent director Andrew Lauck expected to become Lead Independent Director after the meeting. The compensation program emphasizes pay for performance through cash bonuses tied mainly to Adjusted EBITDA and performance stock units.
Strata Critical Medical, Inc. calls a virtual 2026 annual stockholder meeting on May 28, 2026 at 9:00 a.m. Eastern to elect two Class II directors, ratify Deloitte & Touche LLP as auditor, and hold an advisory Say‑on‑Pay vote on 2025 executive compensation.
The company, formerly Blade Air Mobility, transformed in 2025 into a pure‑play medical logistics and services provider by selling its passenger business to Joby Aviation for approximately $76 million in Joby stock plus up to $45 million in holdbacks and earn‑outs, and acquiring Keystone Perfusion Services. It now operates Logistics and Clinical segments serving transplant and cardiovascular surgery customers.
Governance highlights include a classified Board, Co‑Chief Executive Officers William A. Heyburn and Melissa M. Tomkiel, and former CEO Robert Wiesenthal as Non‑Executive Chairman, with independent director Andrew Lauck expected to become Lead Independent Director after the meeting. The compensation program emphasizes pay for performance through cash bonuses tied mainly to Adjusted EBITDA and performance stock units.
Velibor Krstic filed an amended Schedule 13D reporting a significant warrant position in Strata Critical Medical, Inc. He beneficially owns 1,139,393 warrants, representing about 12.4% of the 9,166,644 public warrants outstanding as of the issuer’s latest annual report.
Krstic is a Swiss private investor who used approximately 19,380 dollars of personal funds to acquire these warrants, including 374,958 warrants bought on April 8, 2026 at a weighted average price of about 0.011 dollars per warrant. He also holds 26,425 shares of common stock, or roughly 0.03% of the 86,989,143 shares outstanding as of February 24, 2026.
He states that the warrants are significantly undervalued relative to the company’s fundamentals, citing Adjusted EBITDA of 14.1 million dollars and the integration of Keystone Perfusion. Krstic intends to monitor board and management decisions before the May 7, 2026 warrant expiration and may discuss potential actions such as a voluntary exchange offer or amendments to the warrant agreement, while noting no concrete plans under the specified regulatory categories.
Velibor Krstic filed an amended Schedule 13D reporting a significant warrant position in Strata Critical Medical, Inc. He beneficially owns 1,139,393 warrants, representing about 12.4% of the 9,166,644 public warrants outstanding as of the issuer’s latest annual report.
Krstic is a Swiss private investor who used approximately 19,380 dollars of personal funds to acquire these warrants, including 374,958 warrants bought on April 8, 2026 at a weighted average price of about 0.011 dollars per warrant. He also holds 26,425 shares of common stock, or roughly 0.03% of the 86,989,143 shares outstanding as of February 24, 2026.
He states that the warrants are significantly undervalued relative to the company’s fundamentals, citing Adjusted EBITDA of 14.1 million dollars and the integration of Keystone Perfusion. Krstic intends to monitor board and management decisions before the May 7, 2026 warrant expiration and may discuss potential actions such as a voluntary exchange offer or amendments to the warrant agreement, while noting no concrete plans under the specified regulatory categories.
Strata Critical Medical, Inc. investor Velibor Krstic filed a Schedule 13D after accumulating 764,435 public warrants to purchase Class A common stock. These warrants represent about 8.3% of the 9,166,644 public warrants outstanding, bought in Nasdaq open-market trades for roughly $15,231 of personal funds.
Krstic reports holding sole voting and dispositive power over all the warrants and states he acquired them for investment purposes, believing the SRTAW warrants are undervalued relative to the issuer’s fundamentals, including Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. He indicates he may engage with the board, management, sponsor KSL Capital Partners, and other holders before the warrants’ May 7, 2026 expiration, potentially discussing actions such as a voluntary exchange offer or amendments to the Warrant Agreement.
Strata Critical Medical, Inc. investor Velibor Krstic filed a Schedule 13D after accumulating 764,435 public warrants to purchase Class A common stock. These warrants represent about 8.3% of the 9,166,644 public warrants outstanding, bought in Nasdaq open-market trades for roughly $15,231 of personal funds.
Krstic reports holding sole voting and dispositive power over all the warrants and states he acquired them for investment purposes, believing the SRTAW warrants are undervalued relative to the issuer’s fundamentals, including Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. He indicates he may engage with the board, management, sponsor KSL Capital Partners, and other holders before the warrants’ May 7, 2026 expiration, potentially discussing actions such as a voluntary exchange offer or amendments to the Warrant Agreement.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc., formerly Blade Air Mobility, describes its transformation into a focused provider of time‑critical logistics and clinical services for the U.S. transplant and broader healthcare markets. The company now operates two segments, Logistics and Clinical, offering air and ground organ transport, organ placement, surgical recovery, perfusion, preservation and cardiac care services under the Trinity and Keystone brands.
Strata highlights an asset‑light aviation model supplemented by a limited owned aircraft fleet, extensive use of third‑party operators, and proprietary technology to coordinate complex transplant workflows. In 2025 it divested its legacy Passenger business and acquired Keystone Perfusion Services, concentrating on Medical Customers such as transplant centers, hospitals and Organ Procurement Organizations.
The filing emphasizes numerous risks, including continued net losses, integration and divestiture execution, dependence on donor organ availability and reimbursement, operational and aviation safety hazards, climate and geopolitical disruptions, regulatory and privacy obligations, credit‑facility covenants, competition from integrated and device‑based rivals, and the need to recruit and retain specialized clinical, logistics and management talent.
Strata Critical Medical, Inc., formerly Blade Air Mobility, describes its transformation into a focused provider of time‑critical logistics and clinical services for the U.S. transplant and broader healthcare markets. The company now operates two segments, Logistics and Clinical, offering air and ground organ transport, organ placement, surgical recovery, perfusion, preservation and cardiac care services under the Trinity and Keystone brands.
Strata highlights an asset‑light aviation model supplemented by a limited owned aircraft fleet, extensive use of third‑party operators, and proprietary technology to coordinate complex transplant workflows. In 2025 it divested its legacy Passenger business and acquired Keystone Perfusion Services, concentrating on Medical Customers such as transplant centers, hospitals and Organ Procurement Organizations.
The filing emphasizes numerous risks, including continued net losses, integration and divestiture execution, dependence on donor organ availability and reimbursement, operational and aviation safety hazards, climate and geopolitical disruptions, regulatory and privacy obligations, credit‑facility covenants, competition from integrated and device‑based rivals, and the need to recruit and retain specialized clinical, logistics and management talent.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.